Loading stock data…
AVBP
$29.62-0.21 (-0.70%)
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ArriVent BioPharma, Inc. in the Healthcare sector is trading at $29.62. The stock is currently near its 52-week high of $32.14, remaining 35.1% above its 200-day moving average. Technical signals show neutral RSI of 50 and bearish MACD signal, explaining why AVBP maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 50) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$29.62
Potential Upside
5%
Whystock Fair Value$31.10
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus12 analysts
Mean target$42.10+42.1%
Range$25.25 – $50.00
Fundamentals
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is fir...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.37B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.86
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-54.13%
Volume
Today's trading volume
398,691
Recent News
Are You Looking for a Top Momentum Pick? Why ArriVent BioPharma, Inc. (AVBP) is a Great Choice
Does ArriVent BioPharma, Inc. (AVBP) have what it takes to be a top stock pick for momentum investors? Let's find out.
Are Medical Stocks Lagging AstraZeneca (AZN) This Year?
Here is how Astrazeneca (AZN) and ArriVent BioPharma, Inc. (AVBP) have performed compared to their sector so far this year.
Wall Street Analysts Think ArriVent BioPharma, Inc. (AVBP) Could Surge 72.44%: Read This Before Placing a Bet
The mean of analysts' price targets for ArriVent BioPharma, Inc. (AVBP) points to a 72.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Assessing ArriVent BioPharma (AVBP) Valuation After Recent Share Price Momentum And Pipeline Interest
Event driven snapshot of ArriVent BioPharma ArriVent BioPharma (AVBP) shares recently moved following investor attention on its clinical stage oncology pipeline and ongoing trials. This has prompted closer scrutiny of how the stock’s latest price action lines up with its fundamentals. See our latest analysis for ArriVent BioPharma. At a share price of $24.89, ArriVent BioPharma has a 7 day share price return of 16.15% and a 90 day share price return of 19.66%, while the 1 year total...
Are Medical Stocks Lagging ArriVent BioPharma, Inc. (AVBP) This Year?
Here is how ArriVent BioPharma, Inc. (AVBP) and Brainsway Ltd. Sponsored ADR (BWAY) have performed compared to their sector so far this year.